A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn's disease patients in sustained steroid-free remission on combination therapy

Trial Profile

A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn's disease patients in sustained steroid-free remission on combination therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 May 2017

At a glance

  • Drugs Infliximab (Primary) ; Azathioprine; Mercaptopurine; Methotrexate
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms SPARE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top